NewBridge will have exclusive distribution rights in Algeria, Iraq, Libya, and Jordan for CRYSVITA® (burosumab) for the treatment of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO).

Recently, Merus announced that the first patient has been dosed in the phase 3 clinical trial LiGeR-HN2.

On July 26, Belgian biotech company Confo Therapeutics (Confo) announced that it has completed a €60 million Series B financing round.

On June 24, Viking Therapeutics presented preclinical data of their in-house developed Dual Agonists of Amylin and Calcitonin Receptors (DACARs) .

With the completion of this acquisition, RayzeBio has brought BMS a promising pipeline of radiotherapeutic drugs, including its key project RYZ101 (225Ac-DOTATATE).

Johnson & Johnson has halted the development of their co-created anti-epileptic drug, ADX71149 (JNJ-40411813), with Addex Therapeutics after analyzing Phase 2 clinical data.

The paper discusses the identification of a novel negative allosteric modulator of the µ-opioid receptor (µOR) through screening with a DNA-encoded small molecule library.

Danuglipron is an oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. Pfizer plans to conduct dose-optimization studies in the second half of 2024.

Eli Lilly currently holds the throne as the world's most valuable pharmaceutical company by market capitalization.

If approved, crinecerfont will be the first new treatment option for CAH in 70 years and represents a novel therapeutic approach, offering a new treatment method for this rare and severe endocrine disorder.

Radioligand therapy (RLT), as a part of radiopharmaceuticals, delivers high-energy radiation directly to cancer cells by targeting their structural or biochemical mutations.

Avidity Biosciences, a U.S. publicly traded company, announced the latest data from the Phase 1/2 clinical trial FORTITUDE that investigates AOC1020 for treating FSHD.